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ABSTRACT ~ Objective: Agomelatine, a melatonin (MT1/MT2) receptor agonist and 
5-HT2C receptor antagonist, is a new antidepressant and a potential therapeutic option
for major depressive episodes and negative symptoms in persons with schizophrenia.
We investigated such treatment outcomes with respect to antidepressant efficacy, safety,
and tolerability. Methods: We report a consecutive case series of seven patients with
schizophrenia and comorbid major depressive symptoms who received agomelatine for a
period of at least six weeks in addition to stable doses of antipsychotic agents. General
psychopathology, positive, negative and depressive symptoms were assessed with stan-
dardized interviews. Relevant blood parameters were assessed. Results: Depressive
symptoms improved significantly. Positive symptoms remained stable, while negative
symptoms and global psychopathology improved significantly. Agomelatine was well
tolerated in most patients. Conclusions: Our findings provide initial evidence that
agomelatine is safe and efficacious in treating depressive symptoms in patients with
schizophrenia. Furthermore, agomelatine seems to be effective for the treatment of
negative symptoms. Randomized controlled trials are necessary to confirm these first
observations. Psychopharmacology Bulletin. 2012;45(1):35–43.
INTRODUCTION
Depressive and negative symptoms are common in people with schizophre-
nia1–3 and have been associated with poor quality of life4 and with overall worse
outcomes.5,6 Depressive symptoms can occur during a comorbid major depressive
episode. They may also be secondary, e.g. due to adverse effects of antipsychotics7
or a psychological reaction to stress or other comorbid disorders (e.g. substance
use disorders). Depressive symptoms are common throughout various phases of
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the illness in patients with psychotic disorders and do not respond well
to current antipsychotic treatment.1 Different antidepressant agents,
and some atypical antipsychotics, have been successfully used in the
treatment of depressive symptoms in patients with schizophrenia.8–11
However, to our knowledge, there is only one case report on the use of
agomelatine in the treatment of depressive symptoms in schizophrenia
published so far.12
The mode of action of this antidepressant agent is very promising:
Antagonism at the serotonin subtype 2C (5-HT2C) receptor signifi-
cantly improves incentive motivation and therefore has been suggested
as a therapeutic approach to ameliorate the lack of motivation in
patients with schizophrenia and depressive disorders.13–15 Agonism on
the melatonin (MT1/MT2) receptors has clinically significant antide-
pressant and anxiolytic properties.12,16–19 Additionally, agomelatine has
chronobiotic effects, caused by the synergy between the melatonin-
based and monoamine-based psychotropic effects.18,20 Therefore, we
examined safety and efficacy of agomelatine in a case series of patients
with schizophrenia that developed depressive symptoms under contin-
uous antipsychotic treatment.
METHODS
Patients and Therapy
We report on seven patients (three male, four female) that fulfilled the
diagnostic criteria for psychotic lifetime diagnoses and current major
depressive episodes according to the International Classification of
Diseases, 10th Revision (ICD-10), and received agomelatine as antide-
pressant treatment. For patient details see Table 1.
The patients were treated in the outpatient clinic of the Psychiatric
University Hospital Zürich. On average, first onset of psychosis
occurred at 8.71  2.14 (mean  SD) years ago, with 2.43 (1.62) psy-
chotic episodes and 2.71 (1.80) hospitalizations. First depressive
symptoms occurred 3.07 (2.05) years ago, the patients had suffered
2.14 (1.21) previous major depressive episodes before the current
index episode. At treatment initiation, positive symptoms rated by the
Positive and Negative Syndrome Scale (PANSS) were 17 (8.76),
respectively 35.14 (9.86).
Design and Evaluations
We present data of a retrospective case study of persons with schizo-
phrenia and comorbid major depression who received agomelatine as
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antidepressant treatment in our outpatient centre between January and
July 2011. According to the local ethics committee it is permitted to
retrospectively analyse anonymized clinical data for research purposes.
Demographics, laboratory data (serum levels of gamma-glutamyl-
transferase (GGT) and liver enzymes), clinical and psychiatric history,
and psychopharmacological treatment data were assessed retrospec-
tively using electronic charts. Primary endpoint of the study was the
difference of depressive symptoms as measured by the 21-item
Hamilton scale for depression (HAMD)21 and the Calgary depression
scale for schizophrenia (CDSS)22 across four time points (interval of
2 weeks). Secondary endpoints were the difference of anxiety symp-
toms, positive and negative symptoms over time as assessed with the
PANSS and the Hamilton Scale of anxiety symptoms (HAMA).
Regular clinical assessments included the German versions of the
PANSS, Scale for the Assessment of Negative Symptoms (SANS),
CDSS, HAMD and HAMA, starting before the first dose of agomela-
tine. Exploratory outcome measures were treatment adherence and
safety and tolerability of the treatment.
Statistics
Descriptive statistics are given when appropriate (mean  SD). Mean
comparisons were performed by using one-way repeated-measures
ANOVAs (with the factor time to compare the mean scores over four
different time points). Results were corrected for multiple comparisons
using Bonferroni correction. Results were considered significant at
p  0.05. Statistical analyses were performed using SPSS for Windows
version 18.0 statistical software (SPSS Inc, Chicago, Illinois).
RESULTS
Characteristics of the Patients
Three patients were treated with more than one antidepressant drug.
In these cases, agomelatine was used as a second antidepressant because
of insufficient response to the first one. Two patients were additionally
treated with escitaloprame (10 mg/day), and one was treated with ven-
lafaxine (150 mg/day). With respect to antipsychotic treatments, three
patients were treated with risperidone, two with paliperidone, one with
amisulpride, and two received clozapine. Five patients were treated with
one antipsychotic drug, while two received two antipsychotics.
Furthermore, three patients were treated with additional psychotropic
medications, one patient with an anticholinergic medication, and two
PSYCHOPHARMACOLOGY BULLETIN: Vol. 45 · No. 1
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with antiepileptics. Except agomelatine, medications remained stable
during observation time. Agomelatine was administered at a dose
between 25 or 50 mg/day, dependent on the clinical response.
Outcome
The scores in the different scales and subscales are presented in Figure 1.
Through agomelatine treatment at a mean dosage of 35.71
(SD  13.36) mg/d, we found overall significant improvement of
depressive and negative symptoms (CDSS: F  7.89; p  0.001, mir-
rored by a response (50%-reduction of symptoms) in three patients, and
a complete remission of the depressive syndrome in 1 patient, respec-
tively. Furthermore, HAMD21 scores (HAMD21: F  11.55;
p  0.001) and also anxiety symptoms (HAMA: F  3.26; p  0.05)
decreased. In one patient treatment with agomelatine had to be stopped
because of side-effects (see below).
In parallel with improvement of depressive symptoms, we observed an
improvement of the psychotic negative syndrome (PANSS negative:
F  8.05; p  0.001; SANS: F  8.6; p  0.001), associated with a
decrease of global psychotic symptoms (PANSS GP: F  6.15;
p 0.05; PANSS PSY: F  9.41; p  0.001). Psychotic positive symp-
toms remained unchanged over time (PANSS P: F  2.06; p  0.13).
Preexisting psychotropic comedication remained unchanged during the
observation period.
Safety and Adverse Events
The electronic patient records did not show any serious adverse events
(e.g. hepatitis). However, one patient discontinued the treatment with
agomelatine immediately because of intolerable side-effects (namely:
headache, diarrhea, vertigo and nausea). In general we observed com-
mon side-effects such as headache (n  2), dizziness (n  1), diarrhea
(n  1), insomnia (n  2), and sweating (n  1). However, these side-
effects disappeared completely within the first weeks of the treatment if
continued. We observed a marginal and transitional increase of liver
enzymes in one patient (n  1).
DISCUSSION
This case series on agomelatine revealed significant improvement
over time in depressive and anxiety symptoms among patients with
schizophrenia and depressive symptoms. General psychopathology, par-
ticularly negative symptoms also improved, whereas positive psychotic
PSYCHOPHARMACOLOGY BULLETIN: Vol. 45 · No. 1
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symptoms remained consistently stable. According to current lines of
evidence the compound has been studied primary as antidepressant
drug, moreover, agomelatine has anxiolytic and chronobiotic effects.18
However, in the context of schizophrenia and depressive symptoms the
mode of action of agomelatine is of special interest. Patients suffering
from schizophrenia and comorbid major depression are difficult to
treat, not least, because additionally these patients often suffer from
negative symptoms. The antagonism of the 5HT2C receptors and con-
secutive increase of dopamine and norepinephrine concentrations in the
prefrontal cortex could be helpful concerning negative symptoms and
anhedonia, often associated with major depression in schizophrenia.23
In our study we demonstrated effectiveness, good tolerability and safety
of agomelatine in the treatment of depressive symptoms in patients suf-
fering from schizophrenia. Moreover, negative symptoms improved in
most patients. While one patient discontinued the treatment with
agomelatine because of side effects, all other patients tolerated the med-
ication well.
Our retrospective evaluation has several limitations and allows only
cautious interpretation of efficacy and safety features: Because the num-
ber of cases is small, more or different side-effects could occur in a
larger sample. Although co-medications of our patients during the
observational period remained constant, we cannot exclude interactions
that influenced the outcome.
Nevertheless, a strength of this case series is the naturalistic outpa-
tient setting providing evidence that a successful therapy of schizo-
phrenic patients with concomitant negative symptoms and major
depressive episodes is feasible. Uncontrolled case observations are use-
ful as initial evidence about a drug’s efficacy and tolerability. In addition
to pharmacotherapy, it is also important to keep in mind that a combi-
nation of psychosocial treatments, psychotherapy, group therapies and
contingency management therapies are efficient and necessary for a
successful therapy. Randomized-controlled clinical trials are warranted
to confirm our preliminary results. ✤
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